All News

Migraine specialist abandons one problematic drug and maintains its position by filing an NDA the following week.

Only a year after the National Human Genome Research Institute called for improving sequencing technology, two new methods were announced in the same week. What will the goal of a $1000 human genome mean for medicine and disease research?

A .pdf form for reporting promotions and accolades to appear in Pharmaceutical Representative magazine.

Experts offer their opinion on how Takeda's Rozerem, the first non-controlled sleep aid, will be received by doctors and patients.

Teva's recent purchase of Ivax has analysts wondering where the push for bigger and more global generic manufacturing companies will take the industry.

Prescription drug abuse nearly doubled over a three-year period, according to a new report. In addition to the statistics that you may have seen elsewhere, the study’s authors recommend ways to curb this trend including submitting all promotional material for controlled drugs to FDA.

Exactly what is Nonarteritic Ischemic Optic Neuropathy and how might it be linked to the use of ED drugs?

The trend of public/private partnerships to combat diseases of the developing world continues with collaboration between GSK and the International AIDS Vaccine Initiative. We examine the details of the deal, the science GSK plans to use and the future of this trend.

What Pharma Wants From IT Today

If a physician wants to use protected healthcare information (PHI) for research purposes, particularly if the PHI is going to be published as part of research results, an authorization or waiver will be required.

R&D leaders face the unenviable choice of either dividing their time between science and operations, or focusing on one to the detriment of the other.

Part of the value of a drug comes from the supply chain that protects its integrity. There's a similar supply chain that preserves the value of drug information. And it needs help.

A review of the best ads of 2004--and the people that created them.

A recently released report claims pharma hides bad clinical trial results and over-promotes drugs. Tougher regs are being called for.

Cover Story

Employees are most attracted to products they might feel guilty about buying for themselves, but when they have points to redeem, they feel fine about splurging.

TOC

Post-approval studies, at many companies, do not have a consistent strategy that builds networks of investigators.

Conventional wisdom says that generics businesses are a drain on valuable resources. But these units are much less prone to the disastrous drug safety panics that Big Pharma has recently endured.

Recently developed technologies produce clinical quality cells in as few as12 days. Culturing cells in petri dishes can take a month or more.

Cover Story

Johnson & Johnson's pharmaceutical group builds team and relationship skills into performance evaluations. J&J's Robert Wills says, "Such skills are a built-in expectation. It's how people are supposed to do their job. Everyone who participates in an alliance is compensated for behaviors that contribute to mutual success."

OVERVIEW

Pharma companies in Europe believe that it already takes too long for new medicines to reach patients. Separate bodies for efficacy and safety will lead to further delays.

Pharm Exec talks to the newly appointed leaders of the industry's most influential advocacy organizations.

The LazarusEffect

The High Court ruled that Abbott should pay the agreed-on royalty of 5 percent rather than the 2 percent it's been paying. The difference may be worth $392 million

The 2005 Conference